Why the study?
Does early management with antivirals, immunomodulators, ascorbic acid, melatonin, and immunoglobulins improve clinical condition and LVEF in a patient with COVID-19-related fulminant myocarditis?
Population
A 78-year-old man with COVID-19 infection and probable myocarditis
Comparison
Early management with antivirals, immunomodulatory agents, high-dose ascorbic acid, melatonin, and immunoglobulin therapy
Design
Case report
Authors
Loading...
May support multimodal therapy in COVID-19 myocarditis; hypothesis-generating and requires prospective validation.
Does early management with antivirals, immunomodulators, ascorbic acid, melatonin, and immunoglobulins improve clinical condition and LVEF in a patient with COVID-19-related fulminant myocarditis?
Early management with immunomodulatory and supportive therapies may improve cardiac function in elderly patients with COVID-19-related fulminant myocarditis.
Shahrami et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: